Skip to content
DataLookout
Menu

NCT07946757

Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs)
Timeframe: throughout the full study period,an average of 38 weeks

Secondary (3)

HBsAg, HBsAb and HBV DNA levels and changes from baseline
HBsAg seroclearance rate
HBsAg seroconversion rate

Arms and interventions

Group 1Experimental
Group 2Experimental
Group 3Experimental
Group 4Experimental

Drugs: ACT201 Injection, PegIFNα-2b Injection, Tenofovir Alafenamide Fumarate(TAF)

Sites

3 sites in 1 country